Acquisition by Penny Tom of 125000 shares of Equillium at 0.77 subject to Rule 16b-3
| EQ Stock | USD 0.60 0.04 7.14% |
Slightly above 55% of Equillium's retail investors are presently thinking to get in. The analysis of overall sentiment of trading Equillium stock suggests that some investors are interested at this time. Equillium's investing sentiment overview a quick insight into current market opportunities from investing in Equillium. Many technical investors use Equillium stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Equillium | Build AI portfolio with Equillium Stock |
Filed transaction by Equillium Officer Principal Accounting Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Equillium Fundamental Analysis
We analyze Equillium's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Equillium using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Equillium based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
Equillium is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Equillium Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Equillium stock to make a market-neutral strategy. Peer analysis of Equillium could also be used in its relative valuation, which is a method of valuing Equillium by comparing valuation metrics with similar companies.
Peers
Equillium Related Equities
| INMB | INmune Bio | 11.72 | ||||
| ECOR | Electrocore LLC | 7.09 | ||||
| APLT | Applied Therapeutics | 2.13 | ||||
| CRVS | Corvus Pharmaceuticals | 0.46 | ||||
| IMRN | Immuron | 0.60 | ||||
| LYRA | Lyra Therapeutics | 1.17 | ||||
| MTNB | Matinas BioPharma | 3.12 | ||||
| CING | Cingulate | 3.39 |
Additional Tools for Equillium Stock Analysis
When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.